My Top 5 ASCO 2018 Abstracts in Advanced NSCLC (BMIC-036)
Dr. Jack West reviews his top 5 abstracts in the advanced NSCLC track at ASCO 2018, explaining why each is poised to change the landscape of patient care in this setting. (10:17)
Tag Archives: EGFR mutation
Is immunotherapy ineffective in patients with driver mutation-positive advanced NSCLC? Time to walk that back. (BMIC-027)
Dr. Jack West summarizes the evolving data shaping our understanding of the role of immune checkpoint inhibitors for patients with EGFR- or ALK-positive advanced NSCLC, including more recent data that should change our perspective. (10:25)
A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)
Dr. Jack West reviews the new FDA approval for afatinib (Gilotrif) for specific uncommon EGFR mutations, including G719X, L861Q, and S768I, in advanced NSCLC. (6:35)
Should Osimertinib Become First-Line Treatment of Choice for EGFR Mutation-Positive Advanced NSCLC, or Should it Be Saved for Later? (BMIC-017)
Dr. Jack West reviews the pros and cons of using osimertinib first line vs. “saving” it as a second line therapy, trying to determine the optimal sequence for EGFR-directed therapy in advanced EGFR mutation-positive NSCLC. (11:46)
Dacomitinib: Dark Horse EGFR TKI Charges into a Crowded First Line Setting for EGFR Mutation-Positive Advanced NSCLC (BMIC-016)
Dr. Jack West reviews the results of the ARCHER-1050 trial that showed superior efficacy with dacomitinib vs. gefitinib in EGFR mutation-positive NSCLC. Is it too little, too late for dacomitinib, or can it find a place in a crowded first line setting? (7:53)
The FLAURA Trial: Practice-Changing Results for Patients with EGFR Mutation-Positive NSCLC (BMIC-007)
Dr. Jack West reviews data from ESMO 2017 & the NEJM paper on the PACIFIC trial of durvalumab vs. placebo as consolidation after chemoradiation for patients with unresectable stage III NSCLC, focusing especially on why these results are practice-changing. (9:36)